Incb28060
WebCapmatinib (INCB28060, INC280, NVP-INC280) is a novel, ATP-competitive inhibitor of c-MET with IC50 of 0.13 nM in a cell-free assay, inactive against RONβ, as well as EGFR and HER-3. Capmatinib (INCB28060) inhibits Wnt/β-catenin and EMT signaling pathways and induces apoptosis in diffuse gastric cancer positive for c-MET amplification. Phase 1.
Incb28060
Did you know?
WebINCB28060 exhibits picomolar enzymatic potency and is highly specific for c-MET with more than 10,000-fold selectivity over a large panel of human kinases. This inhibitor potently … WebMay 15, 2024 · Capmatinib (INC280, formerly INCB28060) is a highly selective and potent MET inhibitor with in vitro and in vivo activities against preclinical cancer models with MET activation . Capmatinib is being tested both as a single agent and in combination in multiple clinical trials that are guided by biomarker-based patient selection criteria.
WebINCB28060, also known as Capmatinib and INC280, is a novel and ATP-competitive inhibitor of c-Met with IC50 of 0.13 nM. c-Met, also named as hepatocyte growth factor receptor (HGFR) is a receptor tyrosine kinase that is essential for … WebNov 14, 2011 · INCB28060 potently and specifically inhibits c-MET enzyme activity, c-MET–mediated signal transduction, and the c-MET–dependent neoplastic phenotype of …
WebE341458201660 02444280 Tooling Systems WebINCB28060 (CAS 1029712-80-8) Write a review Ask a question Alternate Names: 2-fluoro-N-methyl-4- (7- (quinolin-6-ylmethyl)imidazo [1,2-b] [1,2,4]triazin-2- yl)benzamide Application: INCB28060 is a novel inhibitor of Met (IC50 = 0.13 nM) CAS Number: 1029712-80-8 Purity: ≥99% Molecular Weight: 412.42 Molecular Formula: C 23 H 17 FN 6 O
WebMedChemExpress References: PMID: 21918175 Purpose: The c-MET receptor tyrosine kinase plays important roles in the formation, progression, and dissemination of human Cancer and presents an attractive therapeutic target. This study describes the preclinical characterization of INCB28060, a novel inhibitor of c-MET kinase. Experimental design: …
WebCapmatinib (INC280; INCB28060) dihydrochloride is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor (IC50=0.13 nM). Capmatinib dihydrochloride can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib dihydrochloride potently inhibits c … howden health \u0026 careWebINCB28060, also known as Capmatinib and INC280, is a novel and ATP-competitive inhibitor of c-Met with IC50 of 0.13 nM. c-Met, also named as hepatocyte growth factor receptor … howden heatersWebAbout INCB28060 cMET is a validated target with significant potential in multiple major oncology indications. INCB28060 is a potent cMET inhibitor that has demonstrated favorable pharmacologic activity in relevant cell and animal models and has demonstrated in those models that it can be dosed safely to how many renters in sherman tx accept bitcoinWebMET small molecule inhibitor. Capmatinib (Synonyms: INC280; INCB28060) is a competitive inhibitor with very potent and selective activity against MET compared to other kinases. It has been shown in vitro that cell lines made resistant to erlotinib, an EGFR inhibitor, could be resensitized after capmatinib treatment. howden high temperature synthetic oil sdsWebCapmatinib, also known as INCB28060 and INC280, is an orally bioavailable inhibitor of the proto-oncogene c-Met (hepatocyte growth factor receptor [HGFR]) with potential antineoplastic activity. c-Met inhibitor INC280 selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. howdenhall police station edinburghWebINCB28060, a novel inhibitor of c-MET kinase. INCB28060 exhibits picomolar enzymatic potency and is highly specific for c-MET with more than 10,000-fold selectivity over a … how many representatives does congress haveWebINCB28060, a novel inhibitor of c-MET kinase. INCB28060 exhibits picomolar enzymatic potency and is highly specific for c-MET with more than 10,000-fold selectivity over a … how many representative does each state have